Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Inflammatory cortical demyelination in early multiple sclerosis.
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate.
Immunological mechanisms underlying delayed-type hypersensitivity reactions to glatiramer acetate.
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
Antigen-specific tolerance by autologous myelin Peptide-coupled cells: a phase 1 trial in multiple sclerosis.
Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants.
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)
Multiple sclerosis: risk factors, prodromes, and potential causal pathways.
Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
Pharmacology and therapeutic potential of interferons.
Regenerative cellular therapies for neurologic diseases.
Genzyme receives positive CHMP opinion in the European Union for once-daily, oral AUBAGIO® to treat relapsing-remitting multiple sclerosis
Intermittent self-catheterisation in MS.
Development of cladribine at Scripps for hairy cell leukemia and current results.
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
Chronic cladribine administration increases amyloid Beta Peptide generation and plaque burden in mice.
Limit cycle oscillations in standing human posture.
A genetic screen identifies genes essential for development of myelinated axons in zebrafish.
Zebrafish myelination: a transparent model for remyelination?
Pages
« first
‹ previous
…
105
106
107
108
109
110
111
112
113
…
next ›
last »